Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.53 |
| ▸ | CA1 | P00915 | 11/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185757 | 0.93 | CA2 (0.61) | CA2CA1CA9CA12CA14 | |
| SCHEMBL6252199 | 0.92 | CA1 (0.59) | CA2CA1CA9CA12CA14 | |
| Biphenyl SCHEMBL2902198 | 0.85 | PTGES2 (0.54) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27901606 | 0.84 | CA1 (0.62) | CA2CA1CA9CA12CA14 | |
| SCHEMBL9999688 | 0.79 | ENPP2 (0.54) | NOS1ENPP2 | |
| SCHEMBL8196817 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA14 | |
| SCHEMBL5436203 | 0.76 | CA2 (0.64) | CA2CA1CA9CA12CA14 | |
| SCHEMBL10586812 | 0.76 | TSHR (0.53) | CA2CA1CA9CA12CA14 | |
| SCHEMBL1795003 | 0.76 | CA2 (0.64) | CA2CA1CA9CA12CA14 | |
| SCHEMBL1775181 | 0.76 | CA2 (0.64) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076651-B1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6573288-B1 | Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-1076651-A1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999057102-A1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |